Press Releases
Every day, more lives are transformed all over the world – one healthy habit at a time. Read the latest about how Medifast and the OPTAVIA® movement is impacting people’s lives.
Bradley T. MacDonald, Chairman of the Board of Medifast, Inc.
According to the American Diabetes Association there are 15.7 million diabetics or 6% of the U.S. population. Diabetes is the 7th leading cause of death in the U.S. Diabetes is a chronic disease that has no cure. Medifast, "Your Physician's Answer to Weight Control," has developed a line of meal replacement products that have been certified by the Glycemic Research Institute and are available for sale in May 2002. The company's website medifastdiet.com details the program for all interested parties.
Medifast is proud to announce that the Johns Hopkins Bloomberg School of Public Health's Nutrition and Research Clinic has approved a two-year clinical study to further substantiate the efficacy of this new line of diabetic products developed to improve weight control in obese Type II Diabetics during active weight loss and during the weight maintenance period. The study will also provide a quality of life assessment for patients as it pertains to lifespan and impact on medications.
"The Company is proud to announce the appointment of Mr. Joseph J. DiBartelomeo PHD, a twenty-year Nutri/System veteran in the weight management industry, as Vice President of Clinical Affairs for Medifast. Dr. DiBartelomeo brings 20 years of clinical experience and insight to Medifast as we develop our dynamic business model. He will assist us in reaching the next level of business development and will be instrumental in the launch of our new clinical meal replacement products, to the weight management and diabetic industry," said Mr. MacDonald.
Medifast increased its sales in the first quarter by 34% due to its aggressive product development program to include soy based oatmeal, chicken noodle soup and chili. The company expects the sales of Medifast Plus For Diabetics to be incremental to its clinical weight management meal replacement business.
This release contains forward-looking statements, which may involve known and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.
SOURCE: Medifast, Inc.
Contact: Bradley T. MacDonald, Chairman & Chief Executive Officer of
Medifast, +1-410-581-8042, ext. 231
Website: http://www.medifastdiet.com/